Kynmobi

Mobility decreased, Parkinson's Disease
Treatment
3 FDA approvals
20 Active Studies for Kynmobi

What is Kynmobi

ApomorphineThe Generic name of this drug
Treatment SummaryApomorphine is a drug used to treat the lack of movement associated with Parkinson’s disease. It was first created in 1845 and first used to treat Parkinson’s in 1884. Apomorphine has also been studied as a potential treatment for other conditions, such as vomiting, alcoholism, and other movement disorders. The medication received FDA approval in 2004.
Apokynis the brand name
image of different drug pills on a surface
Kynmobi Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Apokyn
Apomorphine
2004
16

Approved as Treatment by the FDA

Apomorphine, otherwise called Apokyn, is approved by the FDA for 3 uses including Parkinson's Disease (PD) and Mobility decreased .
Parkinson's Disease (PD)
Mobility decreased
Parkinson's Disease

Effectiveness

How Kynmobi Affects PatientsApomorphine is a drug that affects the brain and can help with motor control. It has a short-term effect and not much of the drug is needed for it to be effective. However, patients should be aware of potential side effects, such as nausea and vomiting, feeling sleepy during the day, low blood pressure, mouth irritation, falling, hallucinations, acting in an aggressive or impulsive way, feeling very hot, and an increased risk of heart problems. Taking an anti-nausea medicine called trimethobenzamide before or while taking apomorphine can help reduce these side effects. It is generally recommended to take this
How Kynmobi works in the bodyApomorphine is a drug that binds to dopamine receptors in the brain, which can help with the movement difficulties associated with Parkinson's disease. We don't know exactly how it works, but it appears to have an effect on a specific part of the brain responsible for movement control.

When to interrupt dosage

The prescribed dosage of Kynmobi is dependent on the specified ailment. The amount of dosage also varies as per the delivery technique (e.g. Kit - Sublingual or Liquid - Subcutaneous) outlined in the table beneath.
Condition
Dosage
Administration
Parkinson's Disease
, 30.0 mg/mL, 10.0 mg, 10.0 mg/mL, 15.0 mg, 25.0 mg, 30.0 mg, 20.0 mg
, Subcutaneous, Injection, Injection - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Film, soluble, Kit - Sublingual, Sublingual, Film, soluble - Sublingual, Kit
Mobility decreased
, 30.0 mg/mL, 10.0 mg, 10.0 mg/mL, 15.0 mg, 25.0 mg, 30.0 mg, 20.0 mg
, Subcutaneous, Injection, Injection - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Film, soluble, Kit - Sublingual, Sublingual, Film, soluble - Sublingual, Kit

Warnings

Kynmobi Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Kynmobi.
Common Kynmobi Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Apomorphine.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Apomorphine.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Apomorphine.
Azelastine
Major
Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Apomorphine.
Kynmobi Toxicity & Overdose RiskThose who overdose on apomorphine may experience nausea, low blood pressure, and even loss of consciousness. Treatment of overdose should involve supportive care and measures to alleviate symptoms. The toxic dose of apomorphine in mice has been found to be 145µg/kg.
image of a doctor in a lab doing drug, clinical research

Kynmobi Novel Uses: Which Conditions Have a Clinical Trial Featuring Kynmobi?

45 active trials are in process to investigate the potential of Kynmobi in alleviating symptoms of Parkinson's Disease.
Condition
Clinical Trials
Trial Phases
Parkinson's Disease
39 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1
Mobility decreased
0 Actively Recruiting

Kynmobi Reviews: What are patients saying about Kynmobi?

4.3Patient Review
5/31/2021
Kynmobi for Parkinson's Disease
This drug is very effective in getting my mom unstuck, but unfortunately it comes with the side effect of nausea. We've found that ginger chews help a bit, but ultimately the decision to take this medication or not is a tough one.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kynmobi

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Kynmobi a controlled substance?

"Kynmobi is not a controlled substance like morphine and therefore does not have a risk of abuse or dependence."

Answered by AI

When was Kynmobi FDA approved?

"The FDA approved KYNMOBI for the treatment of short-term, intermittent OFF episodes in people with Parkinson's disease in May 2020. Jun 22, 2020"

Answered by AI

What are the side effects of Kynmobi?

"The following effects may occur: nausea, vomiting, mouth pain/sores/numbness, gum swelling, dry mouth, headache, dizziness, drowsiness, tiredness, or runny nose. If you experience any of these effects, tell your doctor or pharmacist."

Answered by AI

What is Kynmobi used for?

"Kynmobi is a medication that works by mimicking the brain chemical dopamine. It is meant to be used to help with "off" time in Parkinson's, which is when symptoms get worse. It can be used up to 5 times per day, in addition to other Parkinson's medications."

Answered by AI

Clinical Trials for Kynmobi

Have you considered Kynmobi clinical trials? We made a collection of clinical trials featuring Kynmobi, we think they might fit your search criteria.Go to Trials
Image of University of Kentucky in Lexington, United States.

Peripheral Nerve Tissue Implantation for Parkinson's Disease

45 - 75
All Sexes
Lexington, KY
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.
Phase 1
Recruiting
University of KentuckyCraig G van Horne, MD, PhD
Image of Austin Clinic PPD in Austin, United States.

LY3962681 for Parkinson's Disease

30 - 80
All Sexes
Austin, TX
The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid (aCSF), no active drug) given into the spinal fluid. During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered into the spinal fluid. * The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 days, 12 to 24 weeks apart. * The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks post Dose 2.
Phase 1
Recruiting
Austin Clinic PPDTravis LewisPrevail Therapeutics
Image of Edward Hines Jr. VA Hospital, Hines, IL in Hines, United States.

Non-Invasive Vagal Nerve Stimulation for Parkinson's Disease

50 - 88
All Sexes
Hines, IL
More than 110,000 US Veterans living with Parkinson's disease (PD) currently receive PD-related care and services from the VA. Fall prevention is a priority for Veterans living PD. Gait disturbances are a major cause for functional dependence and the largest risk factor for falls, institutionalization, and death in PD. This SPiRE addresses the need to advance nonpharmacological rehabilitative health care of Veterans and maximizing functional outcomes by developing a non-invasive, neuromodulatory transcutaneous cervical Vagal Nerve Stimulation as an at-home intervention to improve gait and balance. This pilot clinical trial will assist with future efforts and priorities of the VA to prolong independent living and quality of life by minimizing gait and balance dysfunction experienced by Veterans living with PD.
Waitlist Available
Has No Placebo
Edward Hines Jr. VA Hospital, Hines, ILSandra L. Kletzel, PhD BA
Have you considered Kynmobi clinical trials? We made a collection of clinical trials featuring Kynmobi, we think they might fit your search criteria.Go to Trials
Image of San Francisco VA Medical Center, San Francisco, CA in San Francisco, United States.

Ketamine for Depression in Parkinson's Disease

40 - 80
All Sexes
San Francisco, CA
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression in PD, it may target two of the underlying drivers of the disease: (1) reduced neuroplasticity, or the brain's ability to adapt and remodel itself; and (2) elevated inflammation. The investigators are conducting a randomized, placebo-controlled study to examine if a dose of intravenous (IV) ketamine improves depression in Veterans with PD. The investigators will also examine ketamine's effects on neuroplasticity and inflammation, which will help us understand how ketamine works in PD and if it can be a useful treatment for Veterans with the disease. This study will lay groundwork for a larger clinical trial across multiple VA sites.
Phase 2
Recruiting
San Francisco VA Medical Center, San Francisco, CAEllen R Bradley, MD
Image of Hunter Holmes McGuire VA Medical Center, Richmond, VA in Richmond, United States.

Exoskeleton for Parkinson's Disease

18 - 90
All Sexes
Richmond, VA
Physical therapy approaches for balance and walking deficits in Parkinson's disease (PD) have limited effectiveness, with mostly short-lasting benefits. An exoskeleton is a device that straps to the legs and provides a passive force to assist people to better ambulate. The goal of this study is to establish the feasibility and safety of a lightweight exoskeleton on mobility and fall reduction in people with PD. As most PD patients eventually require assistive mobility devices, the exoskeleton represents a new option for increased, mobility, quality of life, and independence. Qualified subjects will come to the clinic twice weekly for eight weeks (16 total visits) and wear the exoskeleton device while walking under the supervision of a trained kinesiotherapist. Study staff will also interview participants and assess their PD symptoms, quality of life, and overall mobility. This study hopes to establish exoskeletons as modern, standard of care devices, which allow people with PD to maintain more independent and productive lives.
Recruiting
Has No Placebo
Hunter Holmes McGuire VA Medical Center, Richmond, VA (+1 Sites)Jessica B Lehosit
Image of Stanford Neuroscience Health Center in Stanford, United States.

STN+NBM DBS for Mild Cognitive Impairment in Parkinson's Disease

21 - 80
All Sexes
Stanford, CA
The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognitive and cognitive-motor symptoms in individuals with Parkinson's disease. The main question it aims to answer is: Is a combined deep brain stimulation approach targeting the STN and NBM with four DBS leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with Parkinson's disease with Mild Cognitive Impairment. Ten participants are anticipated to be enrolled. Participants will undergo a modification of the traditional STN DBS approach for motor symptoms of PD. In addition to the two leads placed within the STN, two additional leads will be placed with the NBM for treatment of cognitive and cognitive-motor symptoms. Novel stimulation patterns will be used within the NBM to target cognitive and cognitive-motor symptoms using an investigational software. Participants will be followed over two years while receiving this therapy with assessments at baseline and every six months. Assessments will include a combination of neuropsychological evaluations, cognitive assessments, motor tasks (including gait/walking), and questionnaires to evaluate the treatment. Two different surgical trajectories will be used, with half the cohort randomized to each group. This will allow comparison of the impact of surgical trajectory on the intervention.
Recruiting
Has No Placebo
Stanford Neuroscience Health CenterHelen M Bronte-Stewart, MD MSE
Have you considered Kynmobi clinical trials? We made a collection of clinical trials featuring Kynmobi, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security